Elutia (NASDAQ:ELUT) & Jushi (OTCMKTS:JUSHF) Head-To-Head Contrast

Elutia (NASDAQ:ELUT) and Jushi (OTCMKTS:JUSHF) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Elutia has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Jushi has a beta of -0.63, meaning that its share price is 163% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Elutia and Jushi, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	1	0	1	0	2.00
Jushi	0	0	1	0	3.00

Elutia currently has a consensus price target of $6.00, suggesting a potential upside of 630.64%. Given Elutia’s higher probable upside, analysts clearly believe Elutia is more favorable than Jushi.

Institutional & Insider Ownership

74.0% of Elutia shares are held by institutional investors. Comparatively, 21.7% of Jushi shares are held by institutional investors. 17.8% of Elutia shares are held by company insiders. Comparatively, 23.1% of Jushi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Elutia and Jushi”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29 million	2.96	$53.38 million	$0.95	0.86
Jushi	$262.91 million	0.32	-$68.59 million	($0.34)	-1.22

Elutia has higher earnings, but lower revenue than Jushi. Jushi is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elutia and Jushi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elutia	426.93%	-407.37%	-47.08%
Jushi	-24.44%	N/A	-15.46%

Summary

Elutia beats Jushi on 8 of the 13 factors compared between the two stocks.

About Elutia

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

About Jushi

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.